Spark ignites investors; one of year's first five biotech IPOs
This article was originally published in Scrip
Executive Summary
Spark Therapeutics priced its initial public offering at $23 per share and the company's stock closed its first day of trading up 117.4% at $50, showing that investors are willing to place big bets on gene therapy that could cure or substantially reduce treatment burdens for severe diseases and conditions.
You may also be interested in...
Finance Watch: Public Markets Open Back Up For Biopharma Offerings
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Spark Sets Sights On Bringing First Gene Therapy To Market In 2018
A BLA for a potential gene therapy to correct vision loss due to certain inherited retinal disease has been accepted by FDA with a Jan. 12 PDUFA date. The proposed trade name is Luxturna.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.